A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability,Pharmacokinetics, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications

Trial Profile

A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability,Pharmacokinetics, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 May 2018

At a glance

  • Drugs MSB 0011359C (Primary)
  • Indications Colorectal cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors EMD Serono
  • Most Recent Events

    • 16 May 2018 According to the Merck KGaA media release, data from this study will be presented at the American Society of Clinical Oncology Annual Meeting (ASCO) 2018.
    • 03 May 2018 Planned primary completion date changed from 10 Sep 2018 to 25 Jun 2019.
    • 06 Feb 2018 Planned number of patients changed from 702 to 647.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top